Tuesday October 14th
| Afternoon/evening |
Arrivals |
Wednesday October 15 th
| 7:00am - 5:00pm |
Registration |
| 7:00am -7:45am |
Continental Breakfast |
| 7:45am -7:50 am |
Welcome
Robert Swerlick, MD and Dennis Barbour, Esq. |
| 7:50am -8:00 am |
Conference Goals
Lowell Goldsmith, MD
|
| 8:00 am -8:45am |
Keynote Address-"What are your drugs really doing to your patients? Epidemiological approaches to studying drug-induced disease"
Brian Strom, MD, MPH
|
| 8:45am -9:00am |
Systemic Signs of Skin Disease-What Would Irwin Braverman Think?
Mark Udey, MD/PhD
|
| 9:00am - 9:30am |
Treatment-induced Skin Disease
Mario Lacouture, MD |
| 9:30am - 9:45am |
Q & A |
| 9:45am - 10:15am |
Dermatologic-Psychiatric Diseases and the Skin
Francisco Tausk, MD
|
| 10:15am - 10:30am |
Q & A |
| 10:30am - 11:00am |
Co-Morbidity and Skin Disease: The Psoriasis Model
Joel Gelfand, MD
|
11:00am - 11:15am Q & A
11:15am - Noon Panel Discussion-All Speakers/Recap
Facilitator: Robert Swerlick, MD
Address:
Common Needs:
Definitional Issues
Data
Common Opportunities
Laboratory based Research Needs
Patient and Population based research
Noon - 1:00pm Lunch
1:00pm - 2:45pm Concurrent Sessions
I Dermatotoxicity
Panel: Michael Bigby, MD; Edward Cowen, MD, Charles Bennett, MD
Moderator : Michael Bigby, MD
Topics:
- Immune and Genetic Susceptibility Factors
- Available Registries and Data
- Drug-specific versus Malignancy-specific Effects.
- What have we learned about other drug related effects
II Dermatologic-Psychiatric Disease
Panel: Alexa Kimball, MD; Phillip Harvey, MD; Peter Muehrer, PhD
Moderator: Rob Stern, MD
Topics:
- Basic nature of skin associated psychiatric disease
- Skin induced psych disease vs. psych induced skin disease
- De novo psych disease vs. skin aggravated
- Available data sets
- What tools are available to measure psychiatric impact and what tools need to be developed?
- How does this work?
- Insight from basic studies of psyche disease - depression, anxiety
- Treatment of skin disease resulting in improvement of mood disorders and vice versa
- Genetic data
III Cutaneous-Cardiovascular Disease
Panel: Kevin Cooper, MD; Joel Kremer, MD; Eric Yang, MD
Moderator: Martin Weinstock, MD/PhD
Topics:
- End Points (Clinical versus Surrogate)
- Inflammatory Links
- Disease-disease; disease-drug/treatment interrelationships
- Immune and Genetic Susceptibility Factors
- Available Registries and Data ; adequate sample size
- Drug-specific and Disease-specific Effects.
- Lessons Learned
2:45pm - 3:00pm Break
3:00pm- 4:40pm Re-convene: Reports Back From Group Discussions
Facilitator: Alexa Kimball, MD
- Common Needs: Definitional Issues, lessons learned, New Position Data
- Common Opportunities: Laboratory based Research Needs,
- Patient and Population based research
- Other high priority diseases or co-morbidities that should be addressed
4:40pm - 5:00pm Break
5:00pm - 5:30pm Susceptibility to Diseases and Side Effects; What Genomic Studies Will Show
Julia Segre, PhD, NIGMS
5:45pm - 6:45pm Cocktail Reception
Thursday October 16 th
7:00am - 9:00am Registration
7:15am - 8:00am Continental Breakfast
8:00am - 9:20am Registry Panel
- Data needs-how serious, urgency and priority
Ken Katz, MD
- The VA as a Study Base
Robert Lew, PhD
- FDA data
Jonathan Wilkin, MD
- Maryam Asgari, MD
Kaiser Data
9:20am - 9:35am Break
9:35am - 10:30am Continuation of Registry Panel Discussion
Industry Models
Alopecia Areata Registry Model
Madeleine Duvic, MD
10: 30am - 11:00am Next Steps
- Results of Discussions
Lowell Goldsmith, MD
- Organizational Approaches
Dennis Barbour, Esq.
- Co-Morbidity Workshop at 2009 SID Meeting
11:00am -11:15am Future Opportunities-Brian Strom
11:25am -11:30am Closing Remarks
11:30am - 12:30pm Lunch Buffet
12:30pm - 1:30pm Departures |
